Asset manager Bitwise’s decision to set a 0.20% fee on its amended US-based Solana ETF application, which now includes staking, may be a sign of how competitive the product could get among ETF issuers ...

Two major crypto ETF issuers are joining the rush to bring crypto asset staking to the U.S. Bitwise and 21Shares each unveiled updates to their crypto funds on Tuesday, cutting fees and adding staking ...

Crypto’s Oct. 10 plunge looks more like a stress test than a regime change, Bitwise Chief Investment Officer Matt Hougan wrote in his Oct. 14 memo. Hougan links the sell-off to a late-Friday post from ...

Benzinga and Yahoo Finance LLC may earn commission or revenue on some items through the links below. Solana is likely to be the winner in the stablecoin and tokenization wave, according to Bitwise ...

The crypto market faced its biggest leveraged wipeout in history last weekend, but the turbulence won’t leave a lasting mark, according to Bitwise chief investment officer Matt Hougan. In a Tuesday ...

Flows into bitcoin BTC $102,489.31 exchange-traded funds (ETFs) are on track to set a new quarterly record, according to crypto asset manager Bitwise, which expects a surge in Q4 as institutional ...

Matt Hougan, Chief Investment Officer at Bitwise, shared his perspective on last week's crypto flash crash, framing the event through a long-term investment lens. What Happened: In his latest ...

Bitwise Asset Management announced its planned Solana staking exchange-traded fund (ETF) will charge a fee of 0.20%, in the latest salvo by the firm to undercut competitors and attract investor ...

Carefully consider the investment objectives, risk factors, charges, and expenses of the Bitwise GME Option Income Strategy ETF (IGME) (the “Fund”) before investing. This material must be preceded or ...

Market-cap weighted crypto indexes underpin funds that hold huge slugs of bitcoin and ether, but plans for new ones could expand beyond the biggest and well-known coins. The latest comes from S&P ...

Oct 10 (Reuters) - Novo Nordisk (NOVOb.CO), opens new tab has decided to discontinue its cell therapy research and development efforts, a spokesperson for the Danish drugmaker told Reuters on Friday.

We are actively working to enhance your experience by translating more content. However, please be aware that the page you are about to visit has not yet been translated. We appreciate your ...